Literature DB >> 30563683

The most important advances in headache research in 2018.

Messoud Ashina1.   

Abstract

Entities:  

Year:  2019        PMID： 30563683     DOI： 10.1016/S1474-4422(18)30434-4

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  5 in total

Review 1.  Migraine and the trigeminovascular system-40 years and counting.

Authors:  Messoud Ashina; Jakob Møller Hansen; Thien Phu Do; Agustin Melo-Carrillo; Rami Burstein; Michael A Moskowitz
Journal:  Lancet Neurol       Date:  2019-05-31       Impact factor: 44.182

2.  Increase in trigeminal ganglion neurons that respond to both calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in mouse models of chronic migraine and posttraumatic headache.

Authors:  Zhaohua Guo; Katherine Czerpaniak; Jintao Zhang; Yu-Qing Cao
Journal:  Pain       Date:  2021-05-01       Impact factor: 7.926

3.  Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs).

Authors:  Paolo Martelletti; Lars Edvinsson; Messoud Ashina
Journal:  J Headache Pain       Date:  2019-05-23       Impact factor: 7.277

4.  Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy.

Authors:  Damiana Scuteri; Maria Tiziana Corasaniti; Paolo Tonin; Pierluigi Nicotera; Giacinto Bagetta
Journal:  J Headache Pain       Date:  2021-07-30       Impact factor: 7.277

5.  Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine.

Authors:  Damiana Scuteri; Paolo Tonin; Pierluigi Nicotera; Marilù Vulnera; Giuseppina Cristina Altieri; Assunta Tarsitano; Giacinto Bagetta; Maria Tiziana Corasaniti
Journal:  Toxins (Basel)       Date:  2022-08-01       Impact factor: 5.075
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.